Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Sickle cell disease is a group of disorders that affects hemoglobin, and the molecule in red blood cells that delivers oxygen to cells throughout the human body. People with this disease have atypical hemoglobin molecules called hemoglobin S, which can distort the biconcave shape of red blood cells into a sickle, or crescent, shape. The sickle cell anemia is an inherited red blood cell disorder, a condition in which the red blood cells are very weak to carry oxygen throughout the human body. The Beta thalassemia results in the decrease in the synthesis or complete absence of the beta globin chains of hemoglobin. In sickle hemoglobin C the red blood cells are stickier than usual, and thus may clog up the small blood vessels in the bones and other parts of the human body. Sickle beta-zero thalassemia is another type of sickle cell disease which involves globin gene and is similar to sickle cell anemia.

The North America sickle cell disease market is estimated to be valued at US$ 770.5 million in 2021 and is expected to exhibit a CAGR of 16.2% over the forecast period (2021-2028).

Figure 1. North America Sickle Cell Disease Market Share (%) in Terms of Value, By Country, 2021

North America Sickle cell disease  | Coherent Market Insights

Fund raising by key players for boosting research and development for the treatment of sickle cell disease is expected to drive the market growth over the forecast period.

The key players in North America are focusing on fund raising for boosting research and development for the treatment of sickle cell disease. For instance, in March 2019, Imara, Inc., a medical device company, announced that the company raised funds which accounted for US$ 63 million from Series B funding round held by OrbiMed Advisors and Arix Bioscience plc. The fund raised by the company would be utilized for the research and development of IMR-687 which is a phosphodiesterase 9 (PDE9) inhibitor in clinical development as a once a day, oral therapy for the treatment of sickle cell disease (SCD) and thalassemia, and to expand the company’s product pipeline.

request-sample

North America Sickle Cell Disease Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 770.5 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 16.2% 2028 Value Projection: US$ 2,200.5 Mn
Geographies covered:
  • North America: U.S. and Canada
Segments covered:
  • By Disease Type: Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease
  • By Drug Type: Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.

Growth Drivers:
  • Increasing product approvals/ launches for treatment of sickle cell disease (SCD)
  • Fund raising by key players for treatment & awareness of SCD
Restraints & Challenges:
  • Major side effects of pharmacological treatments such as hydroxyurea

Figure 2. North America Sickle Cell Disease Market Share (%), by Drug Type, 2021

North America Sickle cell disease  | Coherent Market Insights

North America Sickle Cell Disease Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The Coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, Coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the sickle cell disease medications businesses of various companies, across the regions such as North America, as COVID 19 pandemic has led to unprecedented lockdown in several regions and as well in North America. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Furthermore, various research institutes and academic institutes focusing on performing clinical trial on effect of COVID-19 on individuals suffering from sickle cell disease. For instance, in June 2020, the U.S. National Human Genome Research Institute (NHGRI) initiated clinical trial on study extent and impact of life changes induced by the COVID-19 pandemic on people living with sickle cell disorders (SCD) in the U.S. The study states that adults living with SCD will be adversely impacted by COVID-19 in terms of stress, anxiety, coping, and sleep. Individuals living with SCD will have higher fear, isolation, anxiety and stress, if they have higher clinical severity. Thus, the impact of Coronavirus (COVID-19) pandemic is expected to limit the growth of the North America sickle cell disease market during the forecast period.

North America Sickle Cell Disease Market: Restraint

Major side effects of the pharmacology treatments such as hydroxyurea is expected to hinder the growth of the North America sickle cell disease market. For instance, according to the report published by Starpearls, an authenticated healthcare library throughout the world and articles reviewed by PubMed (MEDLINE database of references and abstracts on life sciences and biomedical topics), various major side effects of hydroxyurea on the long-term treatment in patients suffering from sickle cell disease such as gastrointestinal, dermatological, reproductive, and pulmonary effects restrain the market growth.

Key Players

Major players operating in the North America sickle cell disease market include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.

Sickle cell disease (SCD) is a group of inherited red blood cell disorders, in which the red blood cells of the individuals become sticky and almost ‘C’ or curved in the shape and therefore the disease is known as sickle cell disease. The sickle cell diseases include sickle cell anemia, sickle cell beta- thalassemia, sickle Hemoglobin C Disease, and others. The various symptoms associated with the sickle cell diseases include anemia, episodes of pain, swelling of hands and feet, and others. Major side effects of hydroxyurea on the long-term treatment in patients suffering from sickle cell disease are gastrointestinal effects such as gastric distress, gastritis, mucositis, and oral mucosa ulcer, dermatological effects such as painful skin ulcers, aphthous ulcers, non-ulcerative toxicity with erythema, and skin infiltration, it can also decrease sperm count and sperm motility in males and can even cause severe interstitial pneumonia. The treatment of the sickle cell disease includes medications and blood transfusions. In some cases of the children and teenagers, a stem cell transplant might also cure the disease.

Market Dynamics

The increasing product approvals by key players for the treatment of sickle cell disease is expected to drive the growth of the North America sickle cell disease market over the forecast period. For instance, in May 2021, Chiesi Farmaceutici S.p.A., a pharmaceutical company, announced that the company had received the U.S. Food Drug and Administration approval for FERRIPROX (deferiprone) indicated for the treatment of transfusional iron overload due to sickle cell disease (SCD) and anemia in pediatric patients of three years old or older and adults.

Key features of the study:

  • This report provides in-depth analysis of the North America sickle cell disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the North America sickle cell disease market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The North America sickle cell disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America sickle cell disease market

Detailed Segmentation:

  • North America Sickle Cell Disease Market, By Disease Type:
    • Sickle Cell Anemia
    • Sickle Beta Thalassemia
    • Sickle Hemoglobin C Disease
  • North America Sickle Cell Disease Market, By Drug Type:
    • Hydroxyurea
    • L-glutamine
    • Crizanlizumab
    • Pain-relievers
    • Voxelotor
    • Others
  • North America Sickle Cell Disease Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • North America Sickle Cell Disease Market, By Country:
    • U.S.
    • Canada
  • Company Profiles
    • Novartis International AG
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bristol-Myers Squibb Company
    • Bluebird Bio
    • Global Blood Therapeutics, Inc.
    • Pfizer Inc.
    • Emmaus Life Sciences, Inc.
    • ADDMEDICA
    • Sangamo Therapeutics, Inc.
    • Acceleron Pharma, Inc.
    • Agios Pharmaceuticals, Inc.
    • Chiesi Farmaceutici S.p.A.
    • Vertex Pharmaceuticals, Inc.
    • Imara, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Country
      • Market Opportunity Map
  3. North America Sickle Cell Disease Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Recent Product Approvals/ Launch
    • Market Trends
    • Key Brand Analysis
    • Key Mergers, Acquisitions, Agreements & Collaboration
    • Regulatory Scenario
    • Epidemiology
    • PEST Analysis
  4. North America Sickle Cell Disease Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Drug Development and Clinical Trial
  5. North America Sickle Cell Disease Market, By Disease Type, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Sickle Cell Anemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Sickle Beta Thalassemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Sickle Hemoglobin C Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  6. North America Sickle Cell Disease Market, By Drug Type, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hydroxyurea
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • L-glutamine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Crizanlizumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Pain-relievers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Voxelotor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  7. North America Sickle Cell Disease Market, By Distribution Channel, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  8. North America Sickle Cell Disease Market, By Country, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Region at Trends
    • U.S.
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017–2028, (US$ million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017–2028, (US$ million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2028, (US$ Million)
    • Canada
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017–2028, (US$ million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017–2028, (US$ million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2028, (US$ Million)
  9. Company Market Share Analysis
    • Company Profiles
      • Novartis International AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Bluebird Bio
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Global Blood Therapeutics, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Emmaus Life Sciences, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • ADDMEDICA
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sangamo Therapeutics, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Acceleron Pharma, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Agios Pharmaceuticals, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Chiesi Farmaceutici S.p.A.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Vertex Pharmaceuticals, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Imara, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 17 market data tables and 25 figures on "Sickle Cell Disease Market” – North America forecast to 2028

FAQgrowicon

Frequently Asked Questions

The North America sickle cell disease market size is estimated to be valued at US$ 770.5 Million in 2021 and is expected to exhibit a CAGR of 16.2 % between 2021 and 2028.
Increasing product approvals and launches for the treatment of sickle cell disease (SCD) and fund raising by key players for the treatment & awareness of SCD are major driving factors for market growth.
Voxelotor is the leading drug type segment in the market.
Major side effects of pharmacological treatments are the major factor restraining growth of the market.
Major players operating in the market include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner